ASH: American Society of Hematology

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, discusses the superior safety and progression-free survival outcomes from the SEQUOIA phase 3 trial, which compared zanubrutinib with bendamustine and rituximab combination therapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma.

Sumit Gupta, MD, of The Hospital for Sick Children in Toronto, Canada, told attendees at the 63rd Annual American Society of Hematology Meeting that biological or genetic factors accounted for some of the gap in survival rates, but not all.

L. Elizabeth Budde, MD, PhD, oncologist and associate professor at City of Hope, discusses the use of mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL) who have received 2 or more prior lines of therapy and addresses potential cost-related implications of the drug compared with CAR T-cell therapy.

Results presented Saturday at the annual meeting of the American Society of Hematology show significant benefits in event-free survival, progression-free survival, and complete response over standard of care.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, provides an overview of the emerging data at ASH 2021 on CAR T-cell therapy as a second- and first-line treatment.

Some of the most anticipated presentations at the 63rd Annual American Society of Hematology (ASH) Meeting and Exposition involve phase 3 results for chimeric antigen receptor (CAR) T-cell therapy in second-line treatment.

Organizers of the 63rd Annual American Society of Hematology Meeting and Exposition have multiple safety precautions in place to host a hybrid meeting in Atlanta December 11-14.

As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.

A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.

The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.

Twelve-month maintenance data from this study demonstrate the survival and response benefits associated with daratumumab, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

Zanubrutinib has a cleaner kinome than ibrutinib in that it hits fewer off-target kinases, said Ian Flinn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.

Doctors who treated patients with sickle cell disease who received an infusion of gene-edited treatment have called it "transformative" for those who live with a chronic condition.

Three researchers presented results on COVID-19 therapies and data of importance to patients with hematological conditions.

Results were released for a leading chimeric antigen receptor (CAR) T-cell therapy candidate in multiple myeloma, along with long-term findings for an early treatment that may soon face competition.

There have been exceptional results seen in CARTITUDE-1, stated Deepu Madduri, MD, assistant professor at the Icahn School of Medicine at Mount Sinai in New York City and associate director of its cellular therapy program.

It’s important to get the medicine and the science right, but we must not lose sight of that human connection between patient and caregiver, emphasized Robert K. Massie, Jr, PhD, MA, of the Society for Progress. Massie will speak during the virtual ASH meeting.

The lead investigator touted the benefits of subcutaneous administration of daratumumab in relapsed multiple myeloma (MM) during a presentation on practice-changing results ahead of the American Society of Hematology annual meeting.

Adding daratumumab to standard-of-care regimens consistently improves outcomes among patients with multiple myeloma, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

A preview of the 62nd annual American Society of Hematology meeting, taking place in a virtual format.

Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

At this year’s American Society of Hematology (ASH) meeting, we will see more on new and different targets we can utilize in myeloma, noted Deepu Madduri, MD, assistant professor at the Icahn School of Medicine in New York City and associate director of its cellular therapy program.

Patients with hematologic malignancies receive less appropriate end-of-life care than patients with solid tumors because of barriers with patients, physicians, and the healthcare system in general, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.

New research shows that carfilzomib in newly diagnosed patients with multiple myeloma resulted in a higher rate of minimal residual disease negativity compared with usual rates, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.

The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care.

The study's primary end point, overall survival, showed that patients taking CC-486 had a 31% lower risk of death than those taking placebo.

The French biotech Servier has an agreement with Allogene Therapeutics, through Pfizer, to market its allogenic chimeric antigen receptor (CAR) T-cell product in the United States if it receives FDA approval.

Symptoms of myeloproliferative neoplasms (MPNs) have a large impact on quality of life for patients and it is important to be able to link them, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.

Results presented at ASH support giving ibrutinib as first-line therapy in chronic lymphocytic leukemia (CLL), and future results may offer insights on whether patients can stop therapy once they have undetectable minimal residual disease (MRD).

Karmanos Cancer Institute, in Detroit, Michigan, established a specialty pharmacy to help alleviate the financial burden many patients face when paying for their oral novel therapeutics.